Alvotech (ALVO) 2024 Annual Report (Form 20-F) Summary
Business Context and Reporting Period
Company: Alvotech (Luxembourg public limited company)
Reporting Period: Fiscal year ended December 31, 2024
Business Model: Vertically integrated biotech company focused on developing and manufacturing biosimilars. The company relies on a global network of commercial partners (e.g., Teva, STADA, Fuji Pharma) for sales and distribution rather than maintaining a direct sales force.
Key Products:
- AVT02 (Simlandi): Biosimilar to Humira (adalimumab). Launched in the U.S. in H1 2024; approved in 58 countries.
- AVT04 (Selarsdi): Biosimilar to Stelara (ustekinumab). Launched in the U.S. in February 2025; approved in U.S., Japan, Canada, and EEA.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric (USD in millions) | 2024 | 2023 |
|---|---|---|
| Total Revenue | $489.7 | $91.4 |
| Product Revenue | $273.5 | $48.7 |
| License & Other Revenue | $216.2 | $42.7 |
| Net Loss | ($231.9) | ($551.7) |
| Adjusted EBITDA | $108.3 | ($291.0) |
| Cash & Cash Equivalents | $51.4 | $11.2 |
| Total Debt (Outstanding) | $1,068.6 | $960.2 |
| Operating Cash Flow | ($236.8) | ($312.2) |
Note: The company reported a net loss of $231.9 million in 2024, a significant improvement from the $551.7 million loss in 2023. Revenue grew 436% year-over-year, driven by U.S. product launches and milestone payments.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased from $91.4 million in 2023 to $489.7 million in 2024. Product revenue jumped 461% to $273.5 million, primarily due to the U.S. launch of AVT02 and AVT04. License revenue increased 406% to $216.2 million, driven by regulatory and development milestones (e.g., AVT03, AVT05, AVT06).
- Debt Refinancing: In July 2024, the company closed a $965.0 million Secured Loan Facility (maturing July 2029) to refinance existing debt, including the Senior Bonds and Convertible Bonds. This reduced the cost of capital and extended maturities.
- Convertible Bond Conversion: Approximately $220.7 million of 2022 Convertible Bonds and Aztiq Convertible Bonds were converted into ~22.1 million ordinary shares in July 2024.
- Equity Offering: In February 2024, the company sold treasury shares for net proceeds of $144 million.
- Joint Venture Exit: Sold its 50% interest in a Chinese joint venture in June 2024 for gross proceeds of $18.0 million, recognizing a net loss of $3.0 million.
- IT Independence: Completed migration from Alvogen's ERP and IT infrastructure to its own systems in Q4 2024.
Guidance, Outlook, and Risks
Outlook & Milestones:
- AVT03, AVT05, AVT06: FDA and EMA reviews are anticipated to be completed in Q4 2025.
- AVT04 (U.S.): Commercial launch occurred in February 2025.
- AVT16: Confirmatory patient study initiated in September 2024.
Management believes the company has sufficient funds to continue operations for the foreseeable future based on existing cash, projected milestone collections, and product revenues. However, the company continues to incur significant expenses and may require additional funding in the future.
Key Risks & Contingencies:- Material Weaknesses in Internal Controls: The company identified material weaknesses in internal control over financial reporting (ICFR) related to insufficient trained professionals, inconsistent control execution, and ineffective IT general controls. The independent auditor issued an adverse opinion on ICFR effectiveness. Remediation is ongoing, including the implementation of a new ERP system.
- Debt Service Obligations: With $1.07 billion in debt, the company faces significant interest obligations. Failure to generate sufficient cash flow could lead to default or bankruptcy.
- Regulatory & Patent Litigation: Ongoing patent litigation with AbbVie in Canada regarding AVT02 (partner JAMP) remains pending. Regulatory approval timelines for pipeline products are uncertain.
- Going Concern Uncertainty: While management asserts a going concern basis, the company has a history of losses and relies on future financing and milestone payments.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of remediation plans for the material weaknesses in ICFR and the timeline for achieving an unqualified audit opinion on internal controls.
- Debt Covenants: Review the specific financial covenants in the $965 million Secured Loan Facility and assess the company's ability to maintain minimum liquidity requirements.
- Regulatory Timelines: Monitor FDA and EMA decision dates for AVT03, AVT05, and AVT06, as delays could impact future revenue projections.
- Commercial Partner Performance: Assess the sales performance of AVT02 and AVT04 through partners (Teva, STADA, etc.) to validate revenue growth sustainability.
- Patent Litigation Status: Track the outcome of the JAMP vs. AbbVie litigation in Canada, which could impact AVT02 revenue in that territory.